//= get_template_directory_uri() ?>
|
Strengthen the value chain KEY HIGHLIGHTS DGC is a leading chemical enterprise in Vietnam, holding a dominant position in the supply of yellow phosphorus — a key raw material for modern industries. In addition, the company has demonstrated its ambition to move further up the industrial chemical value chain through large-scale projects in Nghi Son and Lam Dong. In the short term (2025–2026), the ethanol project in Dak Nong, scheduled to commence operations in Q1/2025, and the Nghi Son – Phase 1 project, expected to be operational in Q2/2026, will add new capacity and enhance DGC’s revenue and profit growth. In the first half of 2025, DGC recorded net revenue of over VND 5,700 billion, up nearly 16.6% year-on-year. Net profit after tax increased by 9% to VND 1,728 billion. With this result, DGC has achieved approximately 54.9% of its full-year revenue target and 52.6% of its after-tax profit plan. DGC currently maintains a healthy balance sheet with more than VND 12 trillion in cash and bank deposits, reflecting the company’s strong financial capacity in preparation for upcoming large-scale projects. RECOMMENDATION |
Using the Free Cash Flow to Firm (FCFF) discounted cash flow valuation method, we determine a target price for DGC at VND 120,000 per share. We recommend a “BUY” rating for DGC with a target price of VND 120,000 per share, implying an expected return of 27% compared to the closing price on October 15, 2025
(EN) GTJASVN RS_DGC Equity Report _Strengthen the value chain_TP120,000_Oct 16 2025
05/02/2026
(EN) GTJASVN RS_FRT Equity Report _Long Chau pharmacy chain continues to spearhead growth _TP188,687_Feb 4, 2026 BUSINESS UPDATES According to the FY2025...
03/02/2026
(EN) GTJASVN_MBB Equity Report_2025 Business Results_Accumulate TP29,600VND_03.02.2026 KEY BUSINESS HIGHLIGHTS In 2025, MBB recorded exceptional growth...
29/01/2026
2026 INVESTMENT STRATEGY Entering 2026, the global and Vietnamese investment landscape continues to present a core paradox: “the most efficient is not...